IMPORTANT NOTICE: Many pages on this site may not display properly for Internet Explorer 11 users. Please consider another browser such as Chrome or Firefox.


[Elevated C5 Acylcarnitine]

Isovaleric Acidemia (IVA)


Differential Diagnosis: Isovaleric Acidemia (IVA), 2-Methylbutyrylglycinuria (2MBG) (also referred to as short/branched chain acyl-CoA dehydrogenase deficiency or SBCAD deficiency); antibiotic-related (pivalic acid derived) artifact. 

Condition Description: IVA and 2MBG result from different defects in the metabolism of the branched chain amino acids, leucine (isovaleryl-CoA dehydrogenase in IVA) and isoleucine (short/branched chain acyl-CoA dehydrogenase in 2MBG). In both conditions specific metabolites accumulate and are potentially toxic. 


  • Contact family to inform them of the newborn screening result and ascertain clinical status (poor feeding, vomiting, lethargy, tachypnea, odor of sweaty feet)
  • Consult with pediatric metabolic specialist
  • Evaluate the newborn; if infant is ill, initiate emergency treatment as indicated by metabolic specialist and transport IMMEDIATELY to tertiary center with metabolic specialist
  • Initiate confirmatory/diagnostic testing as recommended by specialist
  • Educate family about signs, symptoms and need for urgent treatment of metabolic acidosis (poor feeding, lethargy, vomiting, tachypnea, odor of sweaty feet)
  • Report findings to state newborn screening program (Carleigh Soule at 307-777-6297) 

Diagnostic Evaluation: Plasma acylcarnitine analysis confirms the increased C5. Urine organic acid analysis will show isovalerylglycine in IVA and 2-methylbutyrylglycine in most cases of 2MBG. Urine acylglycine and acylcarnitine analysis may also be informative. 

Clinical Considerations: Isovaleric Acidemia presents in the neonate with metabolic ketoacidosis, a “sweaty feet” odor, dehydration, hyperammonemia, ketonuria, vomiting, hypoglycemia, and failure to thrive. Milder variants without neonatal illness exist. Long term prognosis of IVA with appropriate therapy is good. The clinical spectrum of 2MBG is variable. To date, most patients identified by newborn screening with 2MGB are of Hmong decent and remain asymptomatic.  

Additional Information: (Click on the name to take you to the website) 

Genetic Home Reference                                    Wyoming Department of Health                                

Gene Tests                                                       Colorado Newborn Screening                           

New England Consortium                                     American Academy of Pediatrics                


For Algorithm: